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Thrombosis in newborns: 
experience from 31 cases
ABSTRACT
Thrombosis is the result of congenital or acquired prothrombotic risk factors. The incidence of thrombosis in the paediatric 
population is highest in newborns, as about 10% of thrombotic events occur in the first four weeks of life. Haemostasis in 
a newborn, though still developing, is a well balanced mechanism. About 90% of all thrombotic events are due to acquired 
and the rest to congenital risk factors. 
The aim of our study was to estimate the incidence of thrombosis in a population of Slovenian newborns and to study risk 
factors, location and treatment of thrombotic events. 
Inpatient charts of newborns with thrombosis, admitted to a tertiary neonatology centre and paediatric intensive care unit 
between 2004 and 2011, were studied retrospectively. Family history, location, aetiology and treatment of thrombosis were 
analysed. 
Thirty one newborns, 17 boys (54.8%) and 14 girls (45.2%), with 31 thrombotic events were found. There were 17 cases 
(54.8%) of arterial and 14 cases (45.2%) of venous thrombosis. A  family history of thrombophilia was found in two cases 
(6.5%). Twenty six cases (83.9%) were contributed to acquired risk factors and five (16.1%) to congenital aetiology. Four 
cases (12.8%) were treated, two with anticoagulation, one with thrombolysis and one with both. The estimated incidence 
of thrombosis was 0.17 per 1000 live births. Our data showed a higher incidence of thrombosis in Slovenian newborns and 
a higher incidence of congenital prothrombotic risk factors than in the data published so far.
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Introduction
Neonatal haemostasis is a dynamic 
process and changes dramatically in 
the first months of life. (1) It starts to 
develop as early as the 10th week of 
gestation when the foetus starts pro-
ducing all the necessary coagulation 
factors by itself. Although several coa-
gulation factors are present in very low 
concentrations and prolonged prot-
hrombin time and activated partial 
thromboplastin time are usually pre-
sent in newborns, haemostasis in a 
normal situation still works as a well 
balanced mechanism without a higher 
risk of thrombotic events.  At birth, a 
term newborn has a 30 to 50% lower 
concentration of vitamin K-dependent 
procoagulant factors II, VI, IX, X, contact 
factors XI, XII, precalicrein and high-
molecular weight kininogen. On the 
other hand, the concentration of anti-
coagulant factors, such as protein C, 
S, antithrombin and heparin cofactor 
II, is also lower. The fibrinolytic process 
is also diminished due to decreased 
concentration and activity of plasmi-
nogen and increased concentration of 
plasminogen activator inhibitors. The 
concentration of these factors rises in 
the next weeks of life and reaches adult 
values at about 6 months of life.
Generally, a thrombotic event is the 
result of congenital or acquired prot-
hrombotic risk factors. (2) The inciden-
ce of thrombosis in the paediatric popu-
lation is highest in newborns, as about 
10% of thrombotic events occur in the 
first four weeks of life. (3) A healthy term 
newborn without prothrombotic risk 
factors does not risk thrombosis more 
than an older child. However, as prot-
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Neonatology and the Department of 
Paediatric Surgery and Intensive Care, 
University Medical Centre Ljubljana, 
between 2004 and 2011, were studi-
ed retrospectively. Risk factors, age at 
presentation, location of the thrombotic 
event, aetiology and the treatment of 
thrombosis were analysed. Thirty one 
newborns, 17 boys (54.8%) and 14 girls 
(45.2%; male vs. female ratio 1.3) with 
31 thrombotic events were found; their 
birth weight was from 620 to 4210 g 
(median 3380 g), their gestational age 
from 24 to 40 weeks (mean 36 weeks). 
Four newborns (12.9%) were small 
for their gestational age and seven 
(26.9%) were premature.
Results
The estimated incidence (data from 
two out of four tertiary centres in the 2 
million Slovenian population) of throm-
bosis was 0.17 per 1000 live births. The 
median age at presentation was two 
days (range 0 to 28 days). There were 
17 cases (55%) of arterial and 14 cases 
(45%) of venous thrombosis (arterial 
vs. venous ratio 1.2). The distribution 
of thrombotic events is summarised in 
table 1. Twenty six thrombotic events 
(84%) were attributed to acquired risk 
factors (table 2) and in five cases (16%) 
congenital aetiology was found (table 
3). A family history of thrombophilia was 
positive in two cases (6%); in a mother 
of one child, deficiency of antithrom-
bin was found, and antiphospholipid 
syndrome was found in another. Four 
newborns (13%) were treated, two with 
anticoagulation (low molecular weight 
heparin - LMWH), one with thrombol-
ysis (alteplase) and one with both.
Discussion
Based on our data, the estimated 
incidence of thrombosis in Slovenian 
newborns was 0.17 per 1000 live births 
annually. The reported incidence of 
thrombosis in the neonatal period is 
5.1 per 100.000 live births annually, 
(6) therefore the incidence we found 
is more than 3 times higher. In view of 
the fact that we included only two out 
of four Slovenian tertiary medical cen-
tres, covering about half of Slovenia’s 





Cerebral artery 13 (42%)
Cerebral vein 4 (13%)
Portal vein 4 (13%)
Limb vein 3 (10%)
Limb artery 2 (6%)
Abdominal aorta 2 (6%)
Other location 3 (10%)
Table 2. Acquired prothrombotic risk factors.
Risk factor Number of newborns
Central vascular catheter 7 (27%)
Operation 6 (23%)
Sepsis 4 (15%)
Respiratory distress syndrome 4 (15%)
Necrotising enterocolitis 2 (8%)
Birth asphyxia 2 (8%)
Infant of diabetic mother 1 (4%)





Homozygotic MTHFR mutation 3
Factor V mutation 1
Prothrombin mutation 1
Antithrombin deficiency 1
hrombotic risk factors are more often 
present in this period of life, the likeli-
hood of thrombosis increases almost 
fivefold in comparison to the gene-
ral paediatric population. (4) Around 
90% of all thrombotic events are due to 
acquired and the rest to congenital risk 
factors. (5) The aim of our study was to 
estimate the incidence of thrombosis 
in a population of Slovenian newborns 
and to study risk factors, location and 
treatment of thrombotic events.
Materials and Methods
Inpatient charts of newborns with throm-
bosis, hospitalized in the Department of 
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population, the real incidence could 
be even higher. This could be due to 
a higher incidence of congenital prot-
hrombotic risk factors in our popula-
tion; on the other hand, the diagno-
stic facilities to identify newborns with 
thrombosis may be more sensitive or 
thrombotic events during therapeutic 
procedures more frequent. Further stu-
dies covering the whole population 
are needed to explain our result. The 
great majority of thrombotic events in 
our study were due to acquired risk 
factors, which is in accordance with 
previously published data. The most 
commonly acquired risk factor in our 
group was a central vascular cathe-
ter, which is known to be the most 
common cause of thrombosis in the 
newborn. (7) A catheter has a more 
or less thrombogenic composition, it 
mechanically injures vascular endothe-
lium and changes blood flow by itself 
and by infused substances. Other risk 
factors such as polycythemia, peri-
natal asphyxia, respiratory distress 
syndrome, congenital heart disease, 
necrotizing enterocolitis, dehydration, 
sepsis, renal disease (e.g. congeni-
tal nephrotic syndrome and neonatal 
haemolytic-uremic syndrome) are also 
described and besides these, envi-
ronmental factors such as immobiliza-
tion, surgery, trauma, extracorporeal 
membrane oxygenation should be 
considered. In our group, four (13%) 
newborns were small for gestational 
age and seven (27%) were premature, 
but according to the studies perfor-
med so far no uniform conclusions 
about the role of  intrauterine growth 
restriction or prematurity as risk factors 
were made. (8-11)
Congenital aetiology of thrombosis in 
our study was about five times rarer 
than acquired aetiology. However, the 
incidence of congenital aetiology was 
higher than in previously published 
data. (6,7) The most common congeni-
tal prothrombotic risk factors, such as 
mutation of the factor V gene (G169A), 
prothrombin gene (G20210A), antit-
hrombin deficiency, protein C or prote-
in S deficiency, C6775T homozygous 
mutation of the methylenetetrahydrofo-
late reductase (MTHFR) gene and the 
mutation of lipoprotein(a) gene, which 
are most commonly described in other 
studies,  were also found in our group. 
Despite the fact that the presence of 
more than one risk factor is needed for 
a thrombotic event in the newborn peri-
od, as most children with a single con-
genital prothrombotic risk factor do not 
develop thrombosis until adulthood, 
(12) we did not find coexistence of risk 
factors, either congenital or acquired. 
A step by step laboratory diagnostic 
approach in a newborn with thrombo-
sis of possible congenital aetiology, 
which is generally recommended, was 
used in all our patients according to 
the family history, epidemiological data 
and clinical presentation. Protein C, 
protein S and antithrombin activity are 
usually measured as a first step and 
lipoprotein(a), homocysteine, factor 
VIII and XII concentration as a second. 
The maternal antiphospholipid syn-
drome and transplacentally transferred 
antibodies (lupus anticoagulant, anti-
cardiolipin and anti-2 glycoprotein I) 
can also act as a cofactor in the deve-
lopment of neonatal thrombosis; the 
determination of these antibodies in the 
mother and, if she proves positive in the 
newborn, is essential. At the same time, 
the search for known gene defects, 
such as the G1691A mutation of fac-
tor V, the G20210A mutation of prot-
hrombin and the homozygous C677T 
mutation of MTHFR gene, should be 
performed. If all these tests prove nega-
tive it is suggested that the diagnostic 
procedure should be expanded to even 
rarer causes, such as congenital dysfi-
brinogenemia and congenital dyspla-
sminogenemia. (13)
Our study shows a slight but not impor-
tant predominance of arterial versus 
venous thrombosis. This observation 
corresponds well to the published 
data, where arterial thromboses make 
up about 50% of all neonatal thrombot-
ic episodes. (14) The most common 
location of thrombosis in our study 
was the cerebral artery, which was 
present in almost half of the newborns 
from the group. This location is also 
described as predominant in the lit-
erature, followed by the aorta, the left 
atrium, the renal, the mesenteric artery 
and limb arteries. (14) The distribution 
of thrombosis location in our group 
was slightly different, but it is difficult 
to compare our data to other studies 
due to the low number of cases stud-
ied.  The most common location of 
venous thrombosis in our group was 
the cerebral vein, which is in contrast 
to locations described in the literature, 
where the most common locations are 
deep veins of the extremities, followed 
by pulmonary, renal, hepatic veins, the 
upper and lower vena cava, the right 
atrium, the portal, mesenteric, cerebral 
and retinal veins. (14)
Due to the lack of randomized control-
led trials (RCT), recommendations for 
antithrombotic therapy in newborns 
are based on recommendations for 
adult patients and expert opinions of 
paediatric haematologists and neona-
tologists. These recommendations 
suggest the use of LMWH or unfrac-
tionated heparin for the treatment of 
neonatal thrombosis. (15) For sympto-
matic newborns with severe or several 
concomitant congenital prothrombotic 
risk factors prolonged anticoagulant 
therapy for up to 6 months is recom-
mended. These newborns should also 
receive prophylactic LMWH in risky situ-
ations (e.g. indwelling central vascular 
catheters). Moreover, due to the lack of 
RCTs in this age group, thrombolysis 
is not recommended except if major 
arteries are occluded or if viability of 
an organ or limb is endangered. (16) 
If this is the case, ten days of throm-
bolytic therapy without further antico-
agulant therapy is usually sufficient. 
In our group of patients, thrombolysis 
was used once for abdominal aorta 
thrombosis and once for femoral vein 
thrombosis after an operation for aortic 
coarctation. Only in this case was fur-
ther anticoagulation therapy used. 
Conclusions
Our data showed a higher estimated 
incidence of thrombosis in Slovenian 
newborns and a higher incidence of 
congenital prothrombotic risk factors 
than in the published data.
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